About Synairgen Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. Synairgen s differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com SNG001 (inhaled Interferon beta) applicability to COVID-19
LONDON : A new potentially life-saving inhaler-based treatment which is hoped will protect COVID-19 patients from developing severe illness has begun a
Read more about UK begins major trial for new inhaler-based coronavirus treatment on Business Standard. A new potentially life-saving inhaler-based treatment which is hoped will protect COVID-19 patients from developing severe illness has begun a major trial at UK hospitals.
cases in India rose to 1,04,95,147 with 15,968 infections being reported in a day, while the recoveries surged to 1,01,29,111, pushing the national recovery rate to 96.51 percent, said the Union health ministry in its morning update.
The toll mounted to 1,51,529 with 202 more deaths and the case fatality rate stands at 1.44 percent, the data updated at 8 am showed.
The ministry said the active caseload has fallen to 2,14, 507 which is the lowest after 197 days, and its share in the total cases has further shrunk to 2.04 percent. The total active cases were 2,15,125 on 30 June, 2020.
Of the 17,817 new recoveries , 81.83 percent were reported from 10 states andUTs. At 4,270,Kerala has reported the maximum number of single day recoveries, followed by Maharashtra with 3,282 new recoveries. Chhattisgarh recorded another 1,207 daily recoveries.
Synairgen plc: COVID-19 Clinical Programme Update
Phase III trial design adapted which will expedite results
Phase III trial to commence dosing in UK imminently
Southampton, UK - 18 December 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces updates to the Company s Phase III trial design evaluating SNG001 as a treatment for patients with COVID-19 and positive progress on the regulatory path.
Update to Phase III trial (SG018) protocol in COVID-19 patients
Following discussions with the regulatory agencies, the trial has been amended as follows:
Removal of the lower dose arm, thereby reducing the number of patients required to complete the placebo-controlled trial from 900 patients to 610 patients